 |
|
Use of Sildenafil for Safe Improvement of Erectile Function and Quality of Life in Men With New York Heart Association Classes II and III Congestive Heart Failure
A Prospective, Placebo-Controlled, Double-blind Crossover Trial
Linda J. Webster, MScN;
Evangelos D. Michelakis, MD;
Terry Davis, PhD;
Stephen L. Archer, MD
Arch Intern Med. 2004;164:514-520.
Background Erectile dysfunction (ED) is common in patients with congestive heart failure (CHF) and is often associated with symptoms of depression. Although sildenafil citrate, a phosphodiesterase 5 inhibitor, is effective in treating ED, its use is considered a relative contraindication in CHF. We hypothesized that sildenafil is a safe and effective treatment for ED in patients with New York Heart Association classes II and III CHF and that treatment of ED will improve symptoms of depression and enhance perceived of quality of life.
Methods We studied 35 patients in a prospective, placebo-controlled, crossover trial for 12 weeks. Inclusion required a history of chronic ED and absence of ischemia (negative results from exercise stress test or nuclear perfusion scan) or nitrate use. The tolerability of sildenafil citrate was established by monitoring the ambulatory blood pressure for 4 hours after a single 50-mg dose. Improvement in ED, the primary end point, was assessed using the International Index of Erectile Function survey. The effect of improved erectile function on quality of life and mood was assessed using the Minnesota Living With Heart Failure Questionnaire, the Beck Depression Index, and the Center for Epidemiological Studies–Depression Scale.
Results Sildenafil caused a mean ± SEM asymptomatic decrease in blood pressure of 6 ± 3 mm Hg, and no patient experienced symptomatic hypotension or other significant adverse effects. Sildenafil improved the International Index for Erectile Function (P<.001) and both sets of depression scores. The Living With Heart Failure Questionnaire index also improved with sildenafil (P = .02).
Conclusion Sildenafil is a safe and effective treatment for ED in men with New York Heart Association classes II and III CHF and provides relief of depressive symptoms, explaining an improvement in the perception of quality of life.
From the Department of Medicine (Cardiology), University of Alberta, Edmonton. Ms Webster and Dr Michelakis contributed equally to this study. The authors have no relevant financial interest in this article.
RELATED LETTERS
Efficacy and Safety of Sildenafil in Patients With Congestive Heart Failure
Nasser Mikhail
Arch Intern Med. 2004;164(18):2067-2068.
EXTRACT
| FULL TEXT
Use of Sildenafil Is Safe in Men With Congestive Heart Failure
Hans Mickley and Tina Svenstrup Poulsen
Arch Intern Med. 2004;164(18):2068.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility
Nagendran et al.
Circulation 2007;116:238-248.
ABSTRACT
| FULL TEXT
Erectile Dysfunction in Heart Failure Patients
Schwarz et al.
J Am Coll Cardiol 2006;48:1111-1119.
ABSTRACT
| FULL TEXT
Efficacy and Safety of Sildenafil in Patients With Congestive Heart Failure
Mikhail
Arch Intern Med 2004;164:2067-2068.
FULL TEXT
Use of Sildenafil Is Safe in Men With Congestive Heart Failure
Mickley and Poulsen
Arch Intern Med 2004;164:2068-2068.
FULL TEXT
ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med. 2004;9:131-131.
FULL TEXT
JournalScan
Malik
Heart 2004;90:723-724.
FULL TEXT
Is Sildenafil Safe and Effective for Men with Heart Failure?
Journal Watch Cardiology 2004;2004:3-3.
FULL TEXT
|
